Topics:

Kosan opens TIME-1 pivotal trial of tanespimycin in myeloma

Kosan opens TIME-1 pivotal trial of tanespimycin in myeloma

HAYWARD, California—Kosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment. Approximately 470 patients with first-relapse disease will be randomized to treatment with bortezomib (Velcade) plus tanespimycin or bortezomib alone.

 
Loading comments...
Please Wait 20 seconds or click here to close